Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocolY K Onno Teng, Paul P. Tak, Ronald van Vollenhoven et al.|BMJ Open|2019Cited by 111
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC studyRonald van Vollenhoven, David Gordon, William Stohl et al.|Lupus Science & Medicine|2018Cited by 17